Abstract: Disclosed are methods of treating autism spectrum disorder (ASD) by administering a therapeutically effective amount of an isoprenoid antibiotic to subjects identified with a splicing defect in an ASD associated gene. The method of treating a subject with a neurological disease is carried out by identifying the subject comprising a splicing defect in an autism spectrum disorder (ASD)-associated gene, the target gene being characterized as having an hnRNP L binding site. The subject is treated by administering a spliceopathy rescue agent to repair the splicing defect. Also disclosed are methods of upregulating hnRNP L and hnRNP L targets by administering a therapeutically effective amount of an isoprenoid antibiotic. Methods of screening compounds for use in treating autism spectrum disorder (ASD) are also described.

Abstract: The present invention provides systems for developing and/or testing therapies for prenatal diseases and conditions including Down Syndrome. The present invention also provides diagnostic methods for Down Syndrome involving, in some embodiments, gene expression analyses of fetal RNA and/or detection of expression of particular genes involved in Down Syndrome. Also provided are microarrays and kits useful in prenatal diagnostic applications.

Abstract: The present invention provides systems for assessing neonatal development and/or conditions by analyzing neonatal saliva RNA. Methods of identifying genes involved in neonatal development and/or conditions affecting neonates, are provided. Methods of determining a diagnosis of a neonate comprising detection of one or more differentially expressed genes are also provided.

Abstract: Solid tumor prognosis genes, and methods, systems and equipment of using these genes for the prognosis and treatment of solid tumors. Prognosis genes for a solid tumor can be identified by the present invention. The expression profiles of these genes in peripheral blood mononuclear cells (PBMCs) are correlated with clinical outcome of the solid tumor. The prognosis genes of the present invention can be used as surrogate markers for predicting clinical outcome of a solid tumor in a patient of interest. These genes can also be used to select a treatment which has a favorable prognosis for the solid tumor of the patient of interest.

Abstract: Methods and apparatus for classifying or predicting the classes for samples based on gene expression are described. Also described are methods and apparatus for ascertaining or discovering new, previously unknown classes based on gene expression.

Abstract: Compositions and methods for diagnosing, monitoring, or treating cancers. Genes encoding transmembrane proteins that are over-expressed in colon, lung, breast, prostate, liver, stomach, esophagus, or kidney cancer tissues are identified. These transmembrane genes can be used as biological markers for the detection or diagnosis of cancers. These genes can also serve as targets for cancer therapeutics. In addition, these genes can also be used for screening for anti-cancer drugs.

Abstract: Solid tumor prognosis genes, and methods, systems and equipment of using these genes for the prognosis and treatment of solid tumors. Prognosis genes for a solid tumor can be identified by the present invention. The expression profiles of these genes in peripheral blood mononuclear cells (PBMCs) are correlated with clinical outcome of the solid tumor. The prognosis genes of the present invention can be used as surrogate markers for predicting clinical outcome of a solid tumor in a patient of interest. These genes can also be used to select a treatment which has a favorable prognosis for the solid tumor of the patient of interest.

Abstract: The present invention provides methods, systems and equipment for the prognosis and treatment of renal cell carcinoma (RCC) or other solid tumors. Genes prognostic of clinical outcomes of a solid tumor can be identified according to the present invention. The expression profiles of these genes in peripheral blood mononuclear cells (PBMCs) of patients who have the solid tumor are correlated with clinical outcome of these patients. Examples of RCC prognosis genes are illustrated in Tables 2 and 3. These genes can be used as surrogate markers for predicting clinical outcome of an RCC patient of interest. These genes can also be used for the selection of a favorable treatment for an RCC patient of interest.

Abstract: The present invention generally relates to a method for an improved treatment for Alzheimer's disease (AD) using immunotherapy, e.g., immunotherapy targeting ? amyloid (A?), e.g., immunotherapy based on AN1792. In one embodiment, the method allows for predicting an adverse clinical response, and therefore allows for an improved safety profile of AN1792. In another embodiment, the method allows for predicting a favorable clinical response, and therefore allows for an improved efficacy profile of AN1792. The methods of the present invention may be combined to predict a favorable clinical response and the lack of an adverse clinical response.

Abstract: Human cell surface molecules CD70 and CD203c are expressed at higher levels in kidney carcinomas, particularly renal cell carcinomas and clear cell renal cell carcinomas, yet are expressed at low levels in normal kidney and other diseased kidney tissue, and at low levels in other tissues. CD70 and CD203c show specificity towards kidney carcinomas, particularly renal cell carcinomas and clear cell renal cell carcinomas and thus can be used as diagnostic markers and therapeutic targets for these diseases. In addition, antibodies or small molecules against these molecules could be used in treatments towards these diseases.

Abstract: Compositions and methods for diagnosing, monitoring, or treating cancers. Genes encoding transmembrane proteins that are over-expressed in colon, lung, breast, prostate, liver, stomach, esophagus, or kidney cancer tissues are identified. These transmembrane genes can be used as biological markers for the detection or diagnosis of cancers. These genes can also serve as targets for cancer therapeutics. In addition, these genes can also be used for screening for anti-cancer drugs.

Abstract: Methods and apparatus for classifying or predicting the classes for samples based on gene expression are described. Also described are methods and apparatus for ascertaining or discovering new, previously unknown classes based on gene expression.

Abstract: Methods and apparatus for classifying or predicting the classes for samples based on gene expression are described. Also described are methods and apparatus for ascertaining or discovering new, previously unknown classes based on gene expression.